Laboratorios Farmaceuticos Rovi (XMAD:ROVI) ROE % Adjusted to Book Value : 1.41% (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi ROE % Adjusted to Book Value?

Laboratorios Farmaceuticos Rovi's ROE % for the quarter that ended in Mar. 2024 was 11.30%. Laboratorios Farmaceuticos Rovi's PB Ratio for the quarter that ended in Mar. 2024 was 7.99. Laboratorios Farmaceuticos Rovi's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was 1.41%.

Laboratorios Farmaceuticos Rovi ROE % Adjusted to Book Value Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi ROE % Adjusted to Book Value Chart

Laboratorios Farmaceuticos Rovi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

3.07

3.12

4.22

11.10

5.56

Laboratorios Farmaceuticos Rovi Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															9.84	3.24	7.91	6.53	1.41

Competitive Comparison of Laboratorios Farmaceuticos Rovi's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratorios Farmaceuticos Rovi's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's ROE % Adjusted to Book Value falls into.

Laboratorios Farmaceuticos Rovi ROE % Adjusted to Book Value Calculation

Laboratorios Farmaceuticos Rovi's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	32.16%	/	5.78
	=	5.56%

Laboratorios Farmaceuticos Rovi's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	11.30%	/	7.99
	=	1.41%

Laboratorios Farmaceuticos Rovi ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 41L:Germany

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.